Peer-reviewed veterinary case report
Use of recombinant interleukin-2 in traumatic disease in veterinary medicine
- Journal:
- RUDN Journal of Agronomy and Animal Industries
- Year:
- 2022
- Authors:
- Oksana A. Gizinger
- Affiliation:
- Peoples’ Friendship University of Russia · RU
Abstract
Тhe article presents analysis of current information on the possibility of using recombinant interleukin-2 in traumatic disease in veterinary medicine. The analysis included publications from the following databases - P ubMed, MedLine, BIOSIS, ToxiNet, CANCERLIT, CINAHL, CISCOM, EMBASE, International Pharmaceutical Abstracts, and NAPRALERT, using 10 keywords and their combinations. It was shown that in trauma of any genesis, an immunodeficiency state occurs associated with an imbalance of Th1/Th2 cytokines. The use of recombinant interleukin-2 restores synthesis of endogenous interleukin-2, provides adequate targeted drug correction of immune dysfunctions, increasing the clinical and immunological effectiveness of therapeutic measures.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://doi.org/10.22363/2312-797X-2022-17-2-210-220